Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing,Cancer Biology & Therapy

当前位置： X-MOL 学术 › Cancer Biol. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing
Cancer Biology & Therapy ( IF 3.6 ) Pub Date : 2023-10-31 , DOI: 10.1080/15384047.2023.2271212
Yuxue Xia _{1,

2} , Lu Zhang ₁ , Wenjuan He ₁ , Huaxiong Pan ₃ , Jun Fang ₁ , Guohui Cui ₁

Affiliation

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare subtype of non-Hodgkin lymphoma. ALK inhibitors are being tried to treat recurrent/refractory ALK+ LBCL. A majority o...

中文翻译：

通过下一代测序鉴定出 ALK 阳性大 B 细胞淋巴瘤的新型 CDK14-ALK 和 CLTC-ALK 融合体对克唑替尼的获得性耐药

间变性淋巴瘤激酶阳性大 B 细胞淋巴瘤 (ALK+ LBCL) 是非霍奇金淋巴瘤的一种罕见亚型。ALK 抑制剂正在尝试治疗复发性/难治性 ALK+ LBCL。大多数...

更新日期：2023-10-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>